Hematopoietic Stem Cell Transplantation for Shwachman-Diamond Syndrome

Area of Science:

• Hematology
• Pediatric Oncology
• Immunology

Background:

• Shwachman-Diamond syndrome (SDS) is a rare genetic disorder characterized by exocrine pancreatic dysfunction, skeletal abnormalities, and bone marrow failure.
• Hematopoietic stem cell transplantation (HSCT) is a potential curative therapy for severe SDS complications.
• Outcomes of HSCT in SDS patients, particularly concerning different indications and donor types, require further elucidation.

Purpose of the Study:

• To evaluate the outcomes of HSCT in a cohort of 52 patients with Shwachman-Diamond syndrome (SDS).
• To compare HSCT efficacy for bone marrow failure (BMF) versus myelodysplasia (MDS)/acute myelogenous leukemia (AML) in SDS patients.
• To identify factors influencing survival, including donor type and preparative regimens.

Main Methods:

• Retrospective analysis of 52 SDS patients undergoing HSCT between 2000 and 2017.
• Categorization of patients based on HSCT indication: BMF (n=39) and MDS/AML (n=13).
• Analysis of donor types (sibling, relative, unrelated) and preparative regimens (myeloablative, reduced intensity).

Main Results:

• For SDS-related BMF, 5-year overall survival was 72%, with graft failure and graft-versus-host disease as primary causes of mortality.
• For SDS-related MDS/AML, survival was poor (15%), with relapse being the main cause of death.
• Survival for SDS-related BMF shows improvement compared to historical data, but challenges persist.

Conclusions:

• HSCT offers improved survival for Shwachman-Diamond syndrome patients with bone marrow failure.
• Current HSCT strategies do not improve survival for SDS-related myelodysplasia or acute myelogenous leukemia.
• Novel therapeutic strategies are needed to address graft failure, graft-versus-host disease, and leukemia in SDS patients.